• English
  • 简体中文
Login Register
Current Location: Home > Dissolution Methods Feedback Help
-
Name Dosage USP Apparatus Speed (RPM's) Medium Volume (mL) Rec.Sampling Times Data Updated
Relugolix Tablet II (Paddle) 50 50 mM Citrate Buffer, pH 5.5 900 5, 10, 15, 20 and 30 2022-07-07
Sodium Iodide I-131 Capsule Develop a dissolution method 2022-07-07
Solifenacin Succinate Suspension II (Paddle) 50 0.1 N HCl 900 5, 10, 15, 20 and 30 2022-07-07
Bismuth Subsalicylate (BiSub)/Metronidazole (Met)/Tetracycline HCl (Tet) BiSub: Tablet (Chewable) /Met:Tablet /Tet: Capsule II (Paddle) 50 BiSub: 0.1 N HCl /Met: Refer to USP /Tet: Refer to FDA's Dissolution Guidance, 2018 900 5, 10, 15, 20 and 30 2022-07-07
Pralsetinib Capsule II (Paddle) with sinker 50 50 mM Sodium Phosphate Buffer, pH 6.8, with 0.4% w/v Cetyl Trimethylammonium Bromide (CTAB) 900 10, 20, 30, 45 and 60 2022-07-07
Bupivacaine Solution (Extended Release), Infiltration II (Paddle) 50 0.025 M Sodium Phosphate Buffer with 0.03% Sodium Dodecyl Sulfate (SDS), pH 7.4 900 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours 2022-07-07
Darunavir(Drv)/Cobicistat (Cobi)/Emtricitabine (Emt)/Tenofovir Alafenamide Fumarate (Taf) Tablet II (Paddle) 75 Drv: 0.05 M Sodium Phosphate Buffer, pH 3.0, 2% Tween 20; For Cobi, Emt and Taf: Citrate Phosphate Buffer, pH 4.2 900 Drv: 10, 15, 20, 30 and 45; For Cobi, Emt and Taf: 5, 10, 15, 20 and 30 2022-07-07
Exenatide Synthetic (2 mg) For Suspension, Extended Release Develop a method to characterize in vitro release 2022-07-07
Cabotegravir Sodium Tablet II (Paddle) 60 0.01N HCl with 0.2% cetyltrimethylammonium bromide (CTAB) 1000 5, 10, 15, 20, 25 and 30 2022-07-07
Lonafarnib Capsule I (Basket) 75 0.2% Sodium Lauryl Sulfate (SLS) in Water 900 5, 10, 15, 20 and 30 2022-07-07
Selpercatinib Capsule II (Paddle) 75 0.1N HCl 900 5, 10, 15, 20 and 30 2022-07-07
Ranolazine Granules (Extended Release) II (Paddle) 50 0.1 N HCl 900 0.5, 1, 2, 3, 4, 6 and 8 hours 2022-07-07
Nifurtimox Tablet II (Paddle) 100 Acetate Buffer, pH 4.5 with 1.0 % Sodium Dodecyl Sulfate (SDS) (for 30 mg strength) and 1.5 % SDS (for 120 mg strength) 900 10, 20, 30, 60 and 75 minutes 2022-07-07
Posaconazole For Suspension (Delayed Release) II (Paddle) 75 Acid stage: 0.01 N HCl; Buffer stage: pH 6.8 Phosphate buffer with 1.3% Tween 80; Acid stage: 750 mL; Acid stage: 120; Buffer stage: 5, 10, 15, 20, 30 and 45 2022-07-07
Cedazuridine/Decitabine Tablet II (Paddle) 75 50 mM phosphate buffer, pH 6.8 900 5, 10, 15 and 30 2022-07-07
Deferiprone (1 GM) Tablet I (Basket) 100 Acidic Stage: 0.1 N HCl, Buffer Stage: 0.05 M Phosphate buffer, pH 6.8. Acid Stage: 2 hours; Buffer Stage: 1, 2, 3 and 4 hours 2022-07-07
Chlorhexidine Gluconate Tablet (Dental) Develop a method to characterize in vitro release 2022-07-07
Selumetinib Capsule II (Paddle) with sinker 75 Sodium Phosphate Buffer, pH 6.5, with 0.5% Polysorbate 80 1000 10, 20, 30, 45 and 60 2022-07-07
Exenatide Synthetic (2 mg/0.85 mL) Suspension, Extended Release Develop a method to characterize in vitro release 2022-07-07
Hydroxyurea Tablet Refer to FDA's Dissolution Guidance, 2018 2022-07-07